NEW YORK, March 13 - Sequenom and CuraGen will work together to probe disease-related genes by combining proteomics and population genetics, the companies said on Wednesday.
In the collaboration, Sequenom will identify genes relevant to disease through its population genetics approach, which applies whole-genome screens to discover relevant SNPs. CuraGen will apply proteomics techniques to characterize gene function, protein interaction and disease pathways, and thereby identify possible drug targets.
The companies did not discuss financial details of the agreement.
Sequenom has already identified more than 120 candidate genes, said company president and CEO Toni Schuh in a statement. CuraGen said its techniques will help validate these candidate genes, and ascertain which make the most viable targets for drug development.
As part of the partnership, CuraGen will also use Sequenom's SNP genotyping techniques to validate drug targets that it has already identfiied.
Sequenom, headquartered in San Diego, uses population genetics to identify common disease-related genes. It is a publicly owned company.
CuraGen, based in New Haven, Conn., uses functional genomics techniques to study genetic variations, gene expression, protein interactions, and potential drugs.